The prevalence of stroke in Nigeria has continued to be a major public health challenge. Recovery from a stroke episode can be a long-impacting process with reduced quality of life outcomes. Past studies have explored the quality of life (QoL) of stroke survivors. However, none have explored the QoL of stroke survivors in Southeastern Nigeria. This study therefore describes the QoL of Nigerian stroke survivors in Southeastern Nigeria. One hundred and one participants (44 male and 58 female) were recruited into the study. QoL domains were assessed using the stroke-specific Health-Related Quality of Life in Stroke Patients (HRQOLISP). The physical domain was significantly lower than other domains measured (mean = 2.52, SD = 0.76), contributing to poor quality of life. On the other hand, the spiritual domain had the greatest positive influence on QoL (mean = 3.70, SD = 0.50). We found the physical domain was the poorest part of stroke survivors' stroke experience. The spiritual domain had a positive impact on improving QoL. There is a need for research on interventions relating to the physical rehabilitation of stroke survivors and a review of how the spiritual domain can be enhanced to improve QoL.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11430842 | PMC |
http://dx.doi.org/10.3390/ijerph21091116 | DOI Listing |
Nephrol Dial Transplant
November 2024
Department of Medicine and Nephrology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Background And Hypothesis: Daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, is approved for treatment of anemia in dialysis patients with CKD in some parts of the world. This subgroup analysis examined the efficacy and safety of daprodustat versus darbepoetin alfa in patients with anemia of CKD undergoing peritoneal dialysis (PD).
Methods: ASCEND-D (NCT02879305) was an open-label, Phase 3 trial; patients with CKD were randomized to daprodustat daily and epoetin alfa (HD patients) or darbepoetin alfa (PD patients).
Curr Med Chem
January 2025
Shree S K Patel College of Pharmaceutical Education and Research, Ganpat University, Mahesana, Gujarat, 384012, India.
Therapeutic hurdles persist in the fight against lung cancer, although it is a leading cause of cancer-related deaths worldwide. Results are still not up to par, even with the best efforts of conventional medicine, thus new avenues of investigation are required. Examining how immunotherapy, precision medicine, and AI are being used to manage lung cancer, this review shows how these tools can change the game for patients and increase their chances of survival.
View Article and Find Full Text PDFCirc Cardiovasc Qual Outcomes
January 2025
Department of Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas (S.G., Nimesh Patel, M.K., M.S.S.).
Int J Dermatol
January 2025
Division of Photobiology and Photomedicine, Department of Dermatology, Henry Ford Health, Detroit, MI, USA.
Few studies discuss the co-management of vitiligo and acquired hyperpigmentation disorders (AHD) such as melasma, erythema dyschromicum perstans, post-inflammatory hyperpigmentation, drug-induced hyperpigmentation, and lichen planus pigmentosus. This review discusses clinical studies examining co-management strategies and identifies current practice gaps. Dermatology Life Quality Index scores are higher in individuals with vitiligo or melasma.
View Article and Find Full Text PDFAnn Transl Med
December 2024
Post-Graduation Department, Faculty of Medical Sciences of Minas Gerais, Belo Horizonte, Brazil.
Background And Objective: Sarcopenia, characterized by the progressive loss of skeletal muscle mass (MM) and muscle function, is a common and debilitating condition in cancer patients, significantly impacting their quality of life, treatment outcomes, and overall survival. The pathophysiology of sarcopenia is multifactorial, involving metabolic, hormonal, and inflammatory changes. Recent research highlights the role of chronic inflammation in the development and progression of sarcopenia, with pro-inflammatory cytokines being key mediators of muscle catabolism.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!